Table 1.
Baseline characteristics
| Dihydroartemisinin–piperaquine (n=20) | Dihydroartemisinin–piperaquine plus tafenoquine 0·42 mg/kg (n=20) | Dihydroartemisinin–piperaquine plus tafenoquine 0·83 mg/kg (n=20) | Dihydroartemisinin–piperaquine plus tafenoquine 1·66 mg/kg (n=20) | |
|---|---|---|---|---|
| Age, years | 17 (14–19) | 13 (12–17) | 15 (12–32) | 15 (13–21) |
| Female | 8 (40%) | 8 (40%) | 6 (30%) | 6 (30%) |
| Male | 12 (60%) | 12 (60%) | 14 (70%) | 14 (70%) |
| Haemoglobin, g/dL | 12·6 (10·9–15·7) | 12·3 (10·2–15·8) | 12·4 (11·1–14·8) | 12·9 (10·8–15·0) |
| Gametocyte prevalence | 20 (100%) | 20 (100%) | 20 (100%) | 20 (100%) |
| Gametocyte density, parasites per μL | 41·5 (12·5–95·9) | 29·5 (12·3–67·8) | 43·7 (18·5–245·0) | 50·1 (17·8–201·8) |
| Asexual parasite prevalence | 12 (60%) | 11 (55%) | 8 (40%) | 15 (75%) |
| Asexual parasite density, parasites per μL | 120 (0–560) | 60 (0–300) | 0 (0–80) | 500 (60–1840) |
Data are median (IQR), n (%), or median (IQR). Gametocyte prevalence and density were calculated from reverse transcriptase quantitative PCR targeting CCP4/PfMGET mRNA (gametocytes). Asexual parasite prevalence and density were assessed by thick film microscopy.